Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Author(s): Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Issue: Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue
Page(s): 342-346
Download in electronic PDF format for $75
Abstract: The purpose of this study was to formulate a 25-mg atenolol capsule starting from a commercial 100-mg atenolol tablet, given the fact that this strength is not available in Palestine and also because 50-mg atenolol tablets failed the splitting uniformity test of the European Pharmacopoeia, and to evaluate the chemical stability and dissolution behavior of the obtained capsules so as to ensure a high-quality product. A high-performance liquid chromatographic system was used for the analysis and quantification of atenolol in the samples studied. Samples of atenolol for analysis were prepared as reported by the United States Pharmacopeia monograph. Disintegration and dissolution tests were performed according to the United States Pharmacopeia. The high-performance liquid chromatography assay indicated that the 25-mg atenolol capsules were stable for four months when stored at ambient temperature conditions. The disintegration time for all atenolol capsules was within the United States Pharmacopeia limits of 15 minutes. Atenolol release profile showed that approximately 90% of atenolol dissolved after 10 minutes. This study is important for patients who need to take one half of a 50-mg tablet, but for whom the splitting process doesn’t give equal halves, and also for modifying the dose for patients with renal or hepatic problems. Therefore, it is possible for the community pharmacist to crush atenolol 100-mg tablets and refill them in new capsules with each containing a precise amount of atenolol, calculated according to body surface area and kidney and liver functions without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost effective dosage form.
Related Keywords:
formulation, atenolol, beta-blocker, hypertension, high blood pressure, arrhythmias, angina pectoris, myocardial infarction, heart attack, stability
Related Categories:
FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL, CARDIOLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
|
Jul/Aug 2012
Pg. 342-346
|
Atenolol 25-, 50-, or 100-mg Capsules
Allen Loyd V Jr
|
Jan/Feb 2015
Pg. 60
|
Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2018
Pg. 233
|
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
|
May/Jun 2003
Pg. 233-239
|
Short-Term Stability of Atenolol in Oral Liquid Formulations
Patel Dipali, Doshi Dharmesh H, Desai Archana
|
Nov/Dec 1997
Pg. 437-439
|
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
|
Mar/Apr 2016
Pg. 167-174
|
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
|
Jan/Feb 2001
Pg. 9-12
|
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III, Everett Eric, Chamberlain Tyler
|
May/Jun 2020
Pg. 194-197
|
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Metoprolol Tartrate 1-mg/mL Injection
Allen Loyd V Jr
|
Jul/Aug 2013
Pg. 333
|
Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 327
|
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
|
Sep/Oct 2022
Pg. 364-368
|
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
|
Sep/Oct 2015
Pg. 414-419
|
Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
|
Sep/Oct 2005
Pg. 402-406
|
Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
|
May/Jun 2009
Pg. 250-253
|
Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Bramwell Bethany L
|
Mar/Apr 2010
Pg. 108-111
|
Labetalol 50-mg Capsules
Allen Loyd V Jr
|
May/Jun 2013
Pg. 233
|
Formulation and Stability of Solutions
Akers Michael J
|
Jan/Feb 2016
Pg. 41-45
|
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Rush Steven D, Vernak Charlene, Zhao Fang
|
Jan/Feb 2017
Pg. 83-87
|
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt
Graves Richard, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V
|
Jul/Aug 2017
Pg. 334-338
|
Return to Top |